Association Between Neutrophil-Lymphocyte Ratio and Oncotype Dx Recurrence Score in Early-Stage Hormonal Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.2166033538338
   PubMed Web of Science ®Google Scholar
• Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055. doi:10.1093/jnci/dju05524777111
   PubMedGoogle Scholar
• Fallahpour S, Navaneelan T, De P, Borgo A. Breast cancer survival by molecular subtype: a population-based analysis of cancer registry data. CMAJ Open. 2017;5(3):E734–E739. doi:10.9778/cmajo.20170030
   PubMedGoogle Scholar
• Kulkarni A, Stroup AM, Paddock LE, Hill SM, Plascak JJ, Llanos AAM. Breast cancer incidence and mortality by molecular subtype: statewide age and racial/ethnic disparities in new Jersey. Cancer Heal Disparities. 2019;3:e1–e17. doi:10.9777/chd.2019.1012
   PubMedGoogle Scholar
• Noone AM, Cronin KA, Altekruse SF, et al. Cancer incidence and survival trends by subtype using data from the surveillance epidemiology and end results program, 1992–2013. Cancer Epidemiol Biomarkers Prev. 2017;26(4):632–641. doi:10.1158/1055-9965.EPI-16-052027956436
   PubMed Web of Science ®Google Scholar
• Dai X, Li T, Bai Z, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 2015;5(10):2929–2943.26693050
   PubMed Web of Science ®Google Scholar
• Kesson EM, Allardice GM, George WD, Burns HJG, Morrison DS. Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women. BMJ. 2012;344:7856. doi:10.1136/bmj.e2718
   Web of Science ®Google Scholar
• Mansour EG, Gray R, Shatila AH, et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. N Engl J Med. 1974;306(13):802–805.
   Google Scholar
• Mansour EG, Gray R, Shatila AH, et al. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis - an intergroup study. J Clin Oncol. 1998;16(11):3486–3492. doi:10.1200/JCO.1998.16.11.34869817265
   PubMed Web of Science ®Google Scholar
• Albain K, Anderson S, Arriagada R, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet. 2012;379(9814):432–444. doi:10.1016/S0140-6736(11)61625-522152853
   PubMed Web of Science ®Google Scholar
• Melisko M. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. Women’s Oncol Rev. 2005;5(1):45–47. doi:10.1080/14733400500093379
   Google Scholar
• Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726–3734. doi:10.1200/JCO.2005.04.798516720680
   PubMed Web of Science ®Google Scholar
• Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol. 2008;26(5):721–728. doi:10.1200/JCO.2007.15.106818258979
   PubMed Web of Science ®Google Scholar
• Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55–65. doi:10.1016/S1470-2045(09)70314-620005174
   PubMed Web of Science ®Google Scholar
• Kwa M, Makris A, Esteva FJ. Clinical utility of gene-expression signatures in early stage breast cancer. Nat Rev Clin Oncol. 2017;14(10):595–610. doi:10.1038/nrclinonc.2017.7428561071
   PubMed Web of Science ®Google Scholar
• Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–121. doi:10.1056/NEJMoa180471029860917
   PubMed Web of Science ®Google Scholar
• Sparano JA, Gray RJ, Makower DF, et al. Clinical outcomes in early breast cancer with a high 21-gene recurrence score of 26 to 100 assigned to adjuvant chemotherapy plus endocrine therapy: a secondary analysis of the TAILORx randomized clinical trial. JAMA Oncol. 2020;6(3):367–374. doi:10.1001/jamaoncol.2019.479431566680
   PubMed Web of Science ®Google Scholar
• Rizki H, Hillyar C, Abbassi O, Miles-Dua S. The utility of Oncotype DX for adjuvant chemotherapy treatment decisions in estrogen receptor-positive, human epidermal growth factor receptor 2-negative, node-negative breast cancer. Cureus. 2020;12(3):1–12. doi:10.7759/cureus.7269
   Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.01321376230
   PubMed Web of Science ®Google Scholar
• Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol. 2012;22(1):33–40. doi:10.1016/j.semcancer.2011.12.00522210179
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi:10.1038/nature0720518650914
   PubMed Web of Science ®Google Scholar
• Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32(19–20):1267–1284. doi:10.1101/GAD.314617.11830275043
   PubMed Web of Science ®Google Scholar
• Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105–113. doi:10.1200/JCO.2009.23.737019917869
   PubMed Web of Science ®Google Scholar
• Pattison CW, Pattison CW, Woods KL, Morrison JM. Lymphocytopenia as an independent predictor of early recurrence in breast cancer. Br J Cancer. 1987;55(1):75–76. doi:10.1038/bjc.1987.153814479
   PubMed Web of Science ®Google Scholar
• Azab B, Bhatt VR, Phookan J, et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol. 2012;19(1):217–224. doi:10.1245/s10434-011-1814-021638095
   PubMed Web of Science ®Google Scholar
• Harowicz MR, Robinson TJ, Dinan MA, et al. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset. Breast Cancer Res Treat. 2017;162:1.28064383
   PubMed Web of Science ®Google Scholar
• Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology. 2008;73(3–4):215–220. doi:10.1159/000127412
   Web of Science ®Google Scholar
• Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009;137(2):425–428. doi:10.1016/j.jtcvs.2008.05.04619185164
   PubMed Web of Science ®Google Scholar
• Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol. 2009;16(3):614–622. doi:10.1245/s10434-008-0267-619130139
   PubMed Web of Science ®Google Scholar
• Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):1–11. doi:10.1093/jnci/dju124
   Google Scholar
• Guo W, Lu X, Liu Q, et al. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: an updated meta-analysis of 17079 individuals. Cancer Med. 2019;8(9):4135–4148. doi:10.1002/cam4.228131197958
   PubMed Web of Science ®Google Scholar
• Wei B, Yao M, Xing C, et al. The neutrophil lymphocyte ratio is associated with breast cancer prognosis: an updated systematic review and meta-analysis. Onco Targets Ther. 2016;9:5567–5575. doi:10.2147/ott.s10841927660475
   PubMed Web of Science ®Google Scholar
• Noh H, Eomm M, Han A. Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J Breast Cancer. 2013;16(1):55–59. doi:10.4048/jbc.2013.16.1.5523593082
   PubMed Web of Science ®Google Scholar
• Corbeau I, Jacot W, Guiu S. Neutrophil to lymphocyte ratio as prognostic and predictive factor in breast cancer patients: a systematic review. Cancers. 2020;12(4):958. doi:10.3390/cancers12040958
   PubMed Web of Science ®Google Scholar
• Grenader T, Plotkin Y, Geffen DB. The preoperative neutrophil/lymphocyte ratio does not correlate with the 21-gene recurrence score in estrogen receptor-positive breast cancer patients. Oncol Res Treat. 2015;38(1–2):24–27. doi:10.1159/000370341
   PubMed Web of Science ®Google Scholar
• Galon J, Pagès F, Marincola FM, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012;10(1). doi:10.1186/1479-5876-10-205
   Web of Science ®Google Scholar
• Koboldt DC, Fulton RS, McLellan MD, et al. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. doi:10.1038/nature1141223000897
   PubMed Web of Science ®Google Scholar
• Faria SS, Fernandes PC, Silva MJB, et al. The neutrophil-to-lymphocyte ratio: a narrative review. Ecancermedicalscience. 2016;10:1–12. doi:10.3332/ecancer.2016.702
   Google Scholar
• McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat. 2006;100(2):229–235. doi:10.1007/s10549-006-9242-816932852
   PubMed Web of Science ®Google Scholar
• Hayes DF, Ethier S, Lippman ME. New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK. Breast Cancer Res Treat. 2006;100(2):237–238. doi:10.1007/s10549-006-9253-516773436
   PubMed Web of Science ®Google Scholar
• Nishijima TF, Deal AM, Williams GR, Guerard EJ, Nyrop KA, Muss HB. Frailty and inflammatory markers in older adults with cancer. Aging. 2017;9(3):650–664. doi:10.18632/aging.10116228273043
   PubMedGoogle Scholar
• Li J, Chen Q, Luo X, et al. Neutrophil-to-lymphocyte ratio positively correlates to age in healthy population. J Clin Lab Anal. 2015;29(6):437–443. doi:10.1002/jcla.2179125277347
   PubMed Web of Science ®Google Scholar
• Rashmi Kumar N, Burns J, Abraham J, et al. NCCN guidelines version 1.2022 breast cancer; 2021. Available from: https://www.nccn.org/guidelines. Accessed December 4, 2021.
   Google Scholar
• Chen Y, Chen K, Xiao X, et al. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study. BMC Cancer. 2016;16(1):1–12. doi:10.1186/s12885-016-2352-8
   Web of Science ®Google Scholar
• Ademuyiwa FO, Miller A, O’Connor T, et al. The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast Cancer Res Treat. 2011;126(3):797–802. doi:10.1007/s10549-010-1329-621197567
   PubMed Web of Science ®Google Scholar
• Zhang L, Hsieh MC, Petkov V, et al. Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004–2015. Breast Cancer Res Treat. 2020;180(2):491–501. doi:10.1007/s10549-020-05557-x32060781
   PubMed Web of Science ®Google Scholar
• Klein ME, Dabbs DJ, Shuai Y, et al. Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis. Mod Pathol. 2013;26(5):658–664. doi:10.1038/modpathol.2013.3623503643
   PubMed Web of Science ®Google Scholar
• Gage MM, Rosman M, Mylander WC, et al. A validated model for identifying patients unlikely to benefit from the 21-Gene recurrence score assay. Clin Breast Cancer. 2015;15(6):467–472. doi:10.1016/j.clbc.2015.04.006.A26072275
   PubMed Web of Science ®Google Scholar
• Tang G, Cuzick J, Costantino JP, et al. Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. J Clin Oncol. 2011;29(33):4365–4372. doi:10.1200/JCO.2011.35.371422010013
   PubMed Web of Science ®Google Scholar
• Dodson A, Okonji D, Assersohn L, et al. Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer. Breast Cancer Res Treat. 2018;168(1):249–258. doi:10.1007/s10549-017-4514-z29128896
   PubMed Web of Science ®Google Scholar
• Crolley VE, Marashi H, Rawther S, et al. The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience. Breast Cancer Res Treat. 2020;180(3):809–817. doi:10.1007/s10549-020-05578-632170635
   PubMed Web of Science ®Google Scholar
• Sparano JA, Crager MR, Tang G, Gray RJ, Stemmer SM, Shak S. Development and validation of a tool integrating the 21-gene recurrence score and clinical-pathological features to individualize prognosis and prediction of chemotherapy benefit in early breast cancer. J Clin Oncol. 2020;39(6). doi:10.1200/jco.20.03007
   PubMed Web of Science ®Google Scholar
• Bain BJ. Ethnic and sex differences in the total and differential white cell count and platelet count. J Clin Pathol. 1996;49(8):664–666. doi:10.1136/jcp.49.8.6648881919
   PubMed Web of Science ®Google Scholar
• Azab B, Camacho-Rivera M, Taioli E. Average values and racial differences of neutrophil lymphocyte ratio among a nationally representative sample of United States subjects. PLoS One. 2014;9(11):e112361. doi:10.1371/journal.pone.011236125375150
   PubMed Web of Science ®Google Scholar
• Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 2015;373(21):2005–2014. doi:10.1056/NEJMoa151076426412349
   PubMed Web of Science ®Google Scholar
• Singh K, He X, Kalife ET, Ehdaivand S, Wang Y, Sung CJ. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results. Breast Cancer Res Treat. 2018;168(1):29–34. doi:10.1007/s10549-017-4619-429230662
   PubMed Web of Science ®Google Scholar
• Conlon N, Ross DS, Howard J, Catalano JP, Dickler MN, Tan LK. Is there a role for oncotype Dx testing in invasive lobular carcinoma? Breast J. 2015;21(5):514–519. doi:10.1111/tbj.1244526271749
   PubMed Web of Science ®Google Scholar
• Kizy S, Huang JL, Marmor S, Tuttle TM, Hui JYC. Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast. Breast Cancer Res Treat. 2017;165(3):757–763. doi:10.1007/s10549-017-4355-928647915
   PubMed Web of Science ®Google Scholar